Business Context and Reporting Period
Company: Inhibrx Biosciences, Inc. (INBX)
Filing Type: Form 8-K (Current Report)
Date of Report: June 15, 2026
Reporting Period: Event-based report regarding regulatory milestones.
Key Financial Metrics
This filing is a regulatory disclosure and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Regulatory Events
- BLA Acceptance: The U.S. Food and Drug Administration (FDA) has accepted for filing the Biologics License Application (BLA) for ozekibart (INBRX-109).
- Indication: Treatment of patients with unresectable or metastatic conventional chondrosarcoma.
- Review Status: The FDA has not identified any filing review issues at this time.
- PDUFA Goal Date: April 14, 2027.
Guidance, Outlook, and Risks
Outlook: The Company anticipates a regulatory decision by the PDUFA goal date of April 14, 2027, pending successful review of the BLA.
Risks and Contingencies: While the BLA was accepted for filing, final approval is not guaranteed. The filing notes that the information is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability for forward-looking statements contained in the press release.
Investor Verification Checklist
- Verify the PDUFA goal date of April 14, 2027, for ozekibart approval.
- Confirm the specific indication approved for review: unresectable or metastatic conventional chondrosarcoma.
- Review the full text of the press release (Exhibit 99.1) for clinical data supporting the BLA.
- Monitor future filings for any FDA Complete Response Letters or approval decisions prior to the PDUFA date.